Latest revenue
$206.7M
as of 2026-02-28
Latest net income
$-26.6M
as of 2026-02-28
Net margin
-12.9%
as of 2026-02-28
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Medicinal Chemicals & Botanical Products (30 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think TLRY is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $576.3M
- Enterprise value
- $579.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.37×
- Dividend yield
- —
- 52-wk high
- —
- 52-wk low
- —
- Beta
- —
- Shares out
- 116.5M
5-year trend
What this company does
Item 1. Business. Our Company Tilray Brands, Inc., a Delaware corporation (collectively, along with its subsidiaries, the “Company”, “Tilray”, “we”, “us” and “our”) is a leading global lifestyle consumer products company, which was incorporated on January 24, 2018 and is headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy, wellness and create…
AI summary unavailable — showing raw filing excerpt
Generated from TLRY's filing dated 2025-07-29
Key risks
Item 1A. Risk Factors. Risks Related to the Cannabis Business Our cannabis business is dependent upon regulatory approvals and licenses, ongoing compliance and reporting obligations, and timely renewals. Our ability to cultivate, process, and sell medical and adult-use cannabis, cannabis-derived extracts and derivative cannabis products in Canada is dependent on maintaining the licenses issued to our operating subsidiaries by Health Canada under the Cannabis Regulations, or CR. These licenses allow us to produce cannabis in bulk and finished forms and to sell and distribute such cannabis in Canada. They also allow us to export medical cannabis in bulk and finished form to and from specified…
AI summary unavailable — showing raw filing excerpt
Generated from TLRY's filing dated 2025-07-29
Profitability
Gross margin
29.3%
3.5%Operating margin
-277.9%
1154.8%Net margin
-266.3%
757.4%Return on equity
-144.7%
1933.2%Return on assets
-105.4%
1716.6%Leverage
Debt / equity
0.37×
64.6%Long-term debt / equity
0.10×
113.6%Debt / assets
27.1%
47.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-02-28 | $206.7M | +11.3% | $-26.6M | +96.6% | -12.9% |
Q4 2025 2025-11-30 | $217.5M | +3.1% | $-44.9M | +47.4% | -20.7% |
Q3 2025 2025-08-31 | $209.5M | +4.7% | $-322.0K | +99.2% | -0.2% |
Q2 2025 2025-05-31 | $224.5M | -2.3% | $-1.27B | -3909.2% | -566.9% |
Q1 2025 2025-02-28 | $185.8M | -1.4% | $-789.4M | -751.6% | -424.9% |
Q4 2024 2024-11-30 | $210.9M | +8.9% | $-85.3M | -74.1% | -40.5% |
Q3 2024 2024-08-31 | $200.0M | +13.1% | $-39.2M | +45.2% | -19.6% |
Q2 2024 2024-05-31 | $229.9M | — | $-31.7M | — | -13.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on TLRY — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$123.5K
Insider selling
$232.9K
Net activity
−$109.3K
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns TLRY
Institutional value
$23.9M
Total shares held
3.8M
Distinct holders
146
-71 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 653.0K | $4.2M | -125.6K (-16.1%) | Trimmed |
| 2 | BlackRock, Inc. | 422.9K | $2.7M | -70.2K (-14.2%) | Trimmed |
| 3 | JANE STREET GROUP, LLC | 373.9K | $2.4M | +165.9K (+79.8%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 348.9K | $2.3M | — | New |
| 5 | Swiss National Bank | 230.5K | $1.5M | +9.1K (+4.1%) | Added |
| 6 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 196.3K | $1.3M | -11.2K (-5.4%) | Trimmed |
| 7 | Headlands Technologies LLC | 175.1K | $1.1M | +50.1K (+40.1%) | Added |
| 8 | DIMENSIONAL FUND ADVISORS LP | 87.8K | $568.1K | +39.8K (+82.9%) | Added |
| 9 | Westend Capital Management, LLC | 86.8K | $561.8K | +5.3K (+6.5%) | Added |
| 10 | Cetera Investment Advisers | 79.8K | $516.2K | -733 (-0.9%) | Trimmed |
| 11 | Legal & General Group Plc | 73.5K | $475.7K | -5.9K (-7.4%) | Trimmed |
| 12 | VANGUARD ASSET MANAGEMENT, Ltd | 71.2K | $460.3K | — | New |
| 13 | AdvisorShares Investments LLC | 63.8K | $412.5K | -5.5K (-7.9%) | Trimmed |
| 14 | Tradewinds Capital Management, LLC | 60.4K | $390.7K | -17 (-0.0%) | Trimmed |
| 15 | ALLSTATE CORP | 56.7K | $367.0K | — | New |
| 16 | Baader Bank Aktiengesellschaft | 47.9K | $292.5K | +7.2K (+17.7%) | Added |
| 17 | Invesco Ltd. | 42.5K | $275.0K | +1.2K (+2.9%) | Added |
| 18 | State of New Jersey Common Pension Fund D | 39.8K | $257.6K | +1.5K (+3.9%) | Added |
| 19 | LPL Financial LLC | 37.3K | $241.6K | -9.5K (-20.3%) | Trimmed |
| 20 | Arizona State Retirement System | 32.0K | $207.0K | +822 (+2.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once TLRY's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.